TransMedics Group, Inc. (TMDX) financials: revenue, earnings and cash flow
Fiscal 2018–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
TransMedics Group’s revenue went from $15M in fiscal 2018 to $605M in fiscal 2025, growth of about 70.2% a year.
Net income in fiscal 2025 was $190M, a net margin of 31.4%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $728M and net income $144M.
Free cash flow was $134M in fiscal 2025 and positive in 1 of the 8 years shown.
The diluted share count rose 2884% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $728M | $605M | $442M | $242M | $93M | $31M | $28M | $26M | $15M |
| Gross profit | $426M | $363M | $262M | $154M | $65M | $21M | $17M | $14M | $6M |
| Operating income | $86M | $109M | $37M | -$29M | -$31M | -$39M | -$26M | -$30M | -$20M |
| Net income | $144M | $190M | $35M | -$25M | -$36M | -$44M | -$29M | -$34M | -$24M |
| EPS (diluted) | $3.66 | $4.87 | $1.01 | $-0.77 | $-1.23 | $-1.60 | $-1.16 | $-2.36 | $-17.48 |
| R&D | $106M | $69M | $56M | $36M | $27M | $22M | $19M | $20M | $14M |
| Revenue growth | — | +37.1% | +82.7% | +158.5% | +197.8% | +10.7% | +9.7% | +76.3% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $112M | $193M | $49M | -$13M | -$46M | -$29M | -$30M | -$32M | -$26M |
| Capital spending | -$68M | -$59M | -$130M | -$152M | -$12M | -$4M | -$455000 | -$165000 | -$418000 |
| Free cash flow | $45M | $134M | -$81M | -$165M | -$58M | -$32M | -$31M | -$32M | -$26M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $41M | $37M | $33M | $20M | $10M | $7M | $2M | $854000 | $144000 |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $489M | $337M | $395M | $201M | $92M | $126M | $81M | $20M |
| Debt | — | $470M | $459M | $457M | $69M | $44M | $35M | $35M | $35M |
| Equity | — | $473M | $229M | $137M | $187M | $68M | $104M | $55M | -$192M |
| Total assets | — | $1.1B | $804M | $706M | $277M | $135M | $152M | $105M | $42M |
| Shares (diluted) | 41M | 41M | 35M | 33M | 30M | 28M | 25M | 14M | 1M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 58.6% | 59.9% | 59.4% | 63.8% | 69.8% | 67.4% | 58.7% | 53.6% | 39.1% |
| Operating margin | 11.9% | 17.9% | 8.5% | -11.9% | -33.6% | -125.6% | -93.0% | -114.5% | -138.1% |
| Net margin | 19.9% | 31.4% | 8.0% | -10.4% | -38.8% | -140.9% | -101.4% | -129.8% | -162.1% |
| FCF margin | 6.1% | 22.1% | -18.3% | -68.2% | -61.8% | -103.2% | -108.3% | -125.6% | -180.1% |
| ROIC | — | 9.1% | 5.4% | -4.5% | -9.7% | -27.9% | -19.0% | -33.0% | — |
| ROE | — | 40.2% | 15.5% | -18.2% | -19.3% | -65.2% | -27.7% | -61.4% | 12.4% |
Frequently asked questions
What is TransMedics Group’s annual revenue?
$605M in fiscal 2025 and $728M over the twelve months to September 30, 2026.
How much profit does TransMedics Group make?
Net income was $190M in fiscal 2025 (net margin 31.4%).
Is TransMedics Group’s revenue growing?
Yes: revenue rose 37.1% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.